Cargando…

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

PURPOSE: To determine the systemic exposure to cisplatin and paclitaxel after adjuvant intraperitoneal administration in patients with advanced ovarian cancer who underwent primary debulking surgery. This could provide an explanation for the high incidence of systemic adverse events associated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, Loek A. W., Lambert, Marie, van Erp, Nielka P., de Vries, Lukas, Chatelut, Etienne, Ottevanger, Petronella B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033566/ https://www.ncbi.nlm.nih.gov/pubmed/36892677 http://dx.doi.org/10.1007/s00280-023-04512-z

Ejemplares similares

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
por: Coccolini, Federico, et al.
Publicado: (2015)

Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer
por: Kim, Myung Joo, et al.
Publicado: (2012)

Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer
por: Ansaloni, L, et al.
Publicado: (2015)

NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
por: Saldanha, Elroy, et al.
Publicado: (2022)

Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study
por: Blinman, Prunella, et al.
Publicado: (2013)

Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study
por: de Jong, Loek A. W., et al.
Publicado: (2020)

Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study
por: de Jong, Loek A. W., et al.
Publicado: (2022)

The addition of sodium thiosulphate to hyperthermic intraperitoneal chemotherapy with cisplatin in ovarian cancer
por: Glennon, Kate, et al.
Publicado: (2021)

Intraperitoneal Paclitaxel Is Useful as Adjuvant Chemotherapy for Advanced Gastric Cancer with Serosal Exposure
por: Kitayama, Joji, et al.
Publicado: (2014)

Improvement of Intraperitoneal Chemotherapy for Rat Ovarian Cancer Using Cisplatin‐containing Microspheres
por: Kumagai, Seisuke, et al.
Publicado: (1996)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model
por: Park, Soo Jin, et al.
Publicado: (2022)

Long-Term Survival Analysis of Intraperitoneal versus Intravenous Chemotherapy for Primary Ovarian Cancer and Comparison between Carboplatin- and Cisplatin-based Intraperitoneal Chemotherapy
por: Eoh, Kyung Jin, et al.
Publicado: (2017)

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
por: Tempfer, Clemens B., et al.
Publicado: (2017)

Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
por: Hue, Hyejeong, et al.
Publicado: (2019)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study
por: Lesnock, J L, et al.
Publicado: (2013)

Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
por: Wang, Wu-yun, et al.
Publicado: (2021)

Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.
por: Kondo, A., et al.
Publicado: (1996)

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
por: Serkies, Krystyna, et al.
Publicado: (2011)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020)

Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy
por: Zhang, Jingjing, et al.
Publicado: (2023)

Mechanistic Insights on Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Huffman, Olivia G., et al.
Publicado: (2023)

Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity
por: Lang, Noemie, et al.
Publicado: (2023)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma
por: Lander, Megan, et al.
Publicado: (2020)

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
por: Wu, Tao, et al.
Publicado: (2018)

Multicenter Retrospective Analysis of Intraperitoneal Paclitaxel and Systemic Chemotherapy for Advanced Gastric Cancer with Peritoneal Metastasis
por: Kim, Dong-Wook, et al.
Publicado: (2020)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study
por: Royer, B, et al.
Publicado: (2012)

A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
por: Chan, Chui-ying, et al.
Publicado: (2021)

Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial
por: Shi, Tingyan, et al.
Publicado: (2018)

Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study
por: He, Xiaoli, et al.
Publicado: (2021)

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
por: Markman, Maurie
Publicado: (2009)

Three ongoing intraperitoneal chemotherapy trials in ovarian cancer
por: Fujiwara, Keiichi
Publicado: (2012)

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
por: Helm, C. William
Publicado: (2015)

Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
por: Jewell, Andrea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_24mr7drfdo6rv4mvst7fm6vsuo